Neuroscience

Neuroscience concept
#Drug discovery #In Focus Report #Market reporting #Neuroscience

New eReport: Advances in neuroscience research

The global prevalence of dementia is approximately 24 million, and is predicted to double every 20 years until at least 2040. Currently, no medications can cure this, though 2024 has proved to be a poignant year of developments in neuroscience, especially considering the challenges faced in previous decades. This guide… Read More

#News

Cell and gene therapies
#AskBio #Gene therapy #Neurodegenerative disorders #Parkinson's #Phase II trial

Gene therapy for Parkinson’s disease progresses to Phase II

A new Phase II trial, REGENERATE-PD, will study AB-1005, an adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic factor (GDNF) gene therapy for the treatment of moderate-stage Parkinson’s disease. The trial will include an estimated 87 subjects with study sites located in the US, UK and… Read More

#News

Neurons
#Alzheimer's #Neurodegenerative disorders #Phase II trial #Regenerative Medicine #Spinogenix

Synapse-regenerating drug could reverse decline in Alzheimer’s

Spinogenix has initiated a Phase II trial to evaluate SPG302 for the treatment of adult participants with mild-to-moderate Alzheimer’s disease (AD), following approval for the trail in Australia. The study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of SPG302 in adult AD participants. Read More

#News

Neurodegenerative disorders
#Dementia #Drug repurposing #Neurodegenerative disorders #University of Iowa

Drugs for enlarged prostate could prevent neurodegeneration

A new study suggests that certain drugs commonly used to treat enlarged prostate may also decrease the risk for dementia with Lewy bodies (DLB) and potentially other neurodegenerative diseases. This observational finding mirrors previous work by the University of Iowa (UI) Health Care team that links… Read More

#News

Neuroscience Parkinson's disease
#Bayer #Biogen #BlueRock Therapeutics #Cell therapy #Ionis Pharmaceuticals #Mission Therapeutics #Neuroscience #Parkinson's #Small molecul #Stem cells #Vaxxinity #Vesper Bio

Exploring new frontiers in Parkinson’s Disease   

With debilitating symptoms including tremor, slow movement, rigidness and pain, Parkinson’s disease remains one of the most feared neurodegenerative conditions. DDW's Megan Thomas reports on the latest clinical progress as pharma and biotech search for new therapies for this currently incurable condition.  Parkinson’s is the most common movement disorder, affecting around… Read More

#Exclusive Content #Trends & Analysis

Brain scan
#France #Minoryx Therapeutics #Neurodegenerative disorders #Phase III trial

Leriglitazone halts progression of fatal neurodegenerative disorder

Leriglitazone has been shown to halt disease progression in adult patients with early cerebral adrenoleukodystrophy (cALD) in a compassionate-use study. cALD is a fatal neurodegenerative disorder that is characterised by growing, demyelinating brain lesions, with death occurring typically within three to four years of onset. Read More

#News

Motor neuron disease awareness day
#Amyotrophic lateral sclerosis (ALS) #Motor neuron disease #Neurodegenerative disorders

Six advances in drug discovery for MND / ALS

Ahead of Motor Neurone Disease (MND) Awareness Day on 21 June, we take a look back over the latest developments in the treatment of MND and amyotrophic lateral sclerosis (ALS). A new UK research partnership In June, UK charity LifeArc pledged £1.5 million to fund a… Read More

#News #Trending News

Neurons in a brain with Alzheimer's disease
#Alchemab Therapeutics #Funding #Neuroscience #Parkinson's #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

Novel antibody with potential in Parkinson’s disease  

Alchemab Therapeutics has been awarded a grant of $595,000 by The Michael J Fox Foundation for Parkinson’s Research (MJFF) to support its Parkinson’s disease (PD) programme.  The grant will fund research performed at Alchemab following its identification of antibodies that target prostaglandin biology in PD, a potentially unique… Read More

#News

#Microbiome #Neurodegenerative disorders #Oncology #Plant-based #Sepsis #Weight loss

New DDW Highlights podcast: 4 June 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The selected news highlights this week report breakthrough findings from early phase research and… Read More

#News

#Microbiome #Neurodegenerative disorders #Oncology #Plant-based #Sepsis #Weight loss

This week in drug discovery (27-31 May) 

News round-up for 27-31 May by DDW Senior Digital Content Editor Diana Spencer. The selected news highlights this week report breakthrough findings from early phase research and development, mainly preclinical studies and Phase I clinical trials, including a drug that can prevent sepsis deaths, a microbiome based immuno-oncology… Read More

#News

Plant-based concept
#Botanical #Jaguar Health #License agreement #Neuroscience #Plant-based #Schizophrenia

Jaguar Health out-licenses plant-based drug for schizophrenia

Jaguar Health’s out-licensing agreement with Magdalena Biosciences to develop novel, natural prescription medicines derived from plants for mental health indications, has been expanded. The agreement now includes the ethnobotanical know-how related to development of a prescription drug compound from a specified medicinal plant for possible schizophrenia and psychoses indications and… Read More

#Business & Investment #News

Dementia
#CNS #IRLAB Therapeutics #Neurodegenerative disorders #Parkinson's #Phase I trial

Drug candidate for apathy enters Phase I trials

Swedish company IRLAB Therapeutics has initiated a Phase I study of IRL757, its drug candidate for apathy – a condition associated with Parkinson’s disease and other CNS diseases. IRL757 has shown positive effects in several preclinical models of cognitive function, including improved motivation. This… Read More

#News

#Blood brain barrier #Calliditas Therapeutics #Cancer #Cancer research #Clinical trials #Drug discovery #Head and neck cancer #Immunotherapy #Neuroscience #Oncology #Plant-based #Schizophrenia #Smoking cessation #Squamous cell carcinoma #Vaping

New DDW Highlights episode: 8 May 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  A leading news story this week has been the announcement of positive Phase II… Read More

#News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Funding #Neurodegenerative disorders #Private investment #University of Texas

$20 million donation supports neurodegeneration research

The University of Texas MD Anderson Cancer Center has been awarded $20 million to strengthen neurodegeneration research. The donation was awarded to the Belfer Neurodegeneration Consortium (BNDC), which aims to develop five new medicines for Alzheimer’s disease and related disorders over the next 10 years, with… Read More

#News